Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked

Cancer Letters

Volumn 380, Issue 1, 2016, Pages 31-38

  Hannes, Sabine ^a   Abhari, Behnaz Ahangarian ^a   Fulda, Simone ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cell death; IAP proteins; Necroptosis; Pancreatic carcinoma; Smac mimetic

Indexed keywords

ANTINEOPLASTIC AGENT; BV 6; CASPASE; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; MIXED LINEAGE KINASE DOMAIN LIKE PROTEIN; PROTEIN KINASE; RECEPTOR INTERACTING PROTEIN 1; RECEPTOR INTERACTING PROTEIN 3; RECEPTOR INTERACTING PROTEIN KINASE 3; REGULATOR PROTEIN; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; AGFG1 PROTEIN, HUMAN; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; BV6 PEPTIDE; CASPASE INHIBITOR; DIABLO PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MAP3K9 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; NUCLEOPORIN; OLIGOPEPTIDE; PEPTIDE CHLOROMETHYL KETONE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK3 PROTEIN, HUMAN; RNA BINDING PROTEIN; SIGNAL PEPTIDE; TNFRSF1A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ARTICLE; AUTOCRINE EFFECT; CELL DEATH; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; NECROPTOSIS; PANCREATIC CANCER CELL LINE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOLOGICAL MIMICRY; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HUMAN; JURKAT CELL LINE; METABOLISM; NECROSIS; PANCREATIC NEOPLASMS; PATHOLOGY; RNA INTERFERENCE; TIME FACTOR;

AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOCRINE COMMUNICATION; BIOLOGICAL MIMICRY; CASPASE INHIBITORS; CASPASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JURKAT CELLS; MAP KINASE KINASE KINASES; MITOCHONDRIAL PROTEINS; NECROSIS; NUCLEAR PORE COMPLEX PROTEINS; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; PARACRINE COMMUNICATION; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA INTERFERENCE; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84976409713     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.05.036     Document Type: Article

References (46)

1. [1] Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Krebs in Deutschland 2007/2008: 8. Ausgabe, 2012 Berlin.
2. [2] GBD 2013 Mortality and Causes of Death Collaborators, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
3. [3] Rahib, L., Smith, B.D., Aizenberg, R., Rosenzweig, A.B., Fleshman, J.M., Matrisian, L.M., Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74 (2014), 2913–2921.
4. [4] Siegel, R., Ma, J., Zou, Z., Jemal, A., Cancer statistics, 2014. CA Cancer J. Clin 64 (2014), 9–29.
5. [5] Fulda, S., Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J. Cell. Mol. Med 13 (2009), 1221–1227.
6. [6] Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., Kroemer, G., Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat. Rev. Mol. Cell Biol 11 (2010), 700–714.
7. [7] Vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S., Walczak, H., Vandenabeele, P., Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol 15 (2014), 135–147.
8. [8] Dondelinger, Y., Declercq, W., Montessuit, S., Roelandt, R., Goncalves, A., Bruggeman, I., et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep 7 (2014), 971–981.
9. [9] Wang, H., Sun, L., Su, L., Rizo, J., Liu, L., Wang, L.F., et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol. Cell 54 (2014), 133–146.
10. [10] Oberst, A., Dillon, C.P., Weinlich, R., McCormick, L.L., Fitzgerald, P., Pop, C., et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471 (2011), 363–367.
11. [11] Fulda, S., Vucic, D., Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov 11 (2012), 109–124.
12. [12] Vogler, M., Walczak, H., Stadel, D., Haas, T.L., Genze, F., Jovanovic, M., et al. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 68 (2008), 7956–7965.
13. [13] Vogler, M., Durr, K., Jovanovic, M., Debatin, K.M., Fulda, S., Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene 26 (2007), 248–257.
14. [14] Fulda, S., Promises and challenges of Smac mimetics as cancer therapeutics. Clin. Cancer Res 21 (2015), 5030–5036.
15. [15] Vogler, M., Walczak, H., Stadel, D., Haas, T.L., Genze, F., Jovanovic, M., et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 69 (2009), 2425–2434.
16. [16] Stadel, D., Mohr, A., Ref, C., MacFarlane, M., Zhou, S., Humphreys, R., et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin. Cancer Res 16 (2010), 5734–5749.
17. [17] Stadel, D., Cristofanon, S., Abhari, B.A., Deshayes, K., Zobel, K., Vucic, D., et al. Requirement of nuclear factor kappaB for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis. Neoplasia 13 (2011), 1162–1170.
18. [18] Giagkousiklidis, S., Vellanki, S.H., Debatin, K.M., Fulda, S., Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene 26 (2007), 7006–7016.
19. [19] Dineen, S.P., Roland, C.L., Greer, R., Carbon, J.G., Toombs, J.E., Gupta, P., et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 70 (2010), 2852–2861.
20. [20] Fulda, S., Therapeutic exploitation of necroptosis for cancer therapy. Semin. Cell Dev. Biol 35 (2014), 51–56.
21. [21] Fulda, S., The mechanism of necroptosis in normal and cancer cells. Cancer Biol. Ther 14 (2013), 999–1004.
22. [22] Varfolomeev, E., Blankenship, J.W., Wayson, S.M., Fedorova, A.V., Kayagaki, N., Garg, P., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131 (2007), 669–681.
23. [23] Fulda, S., Friesen, C., Los, M., Scaffidi, C., Mier, W., Benedict, M., et al. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57 (1997), 4956–4964.
24. [24] Schenk, B., Fulda, S., Reactive oxygen species regulate Smac mimetic/TNFα-induced necroptotic signaling and cell death. Oncogene 34 (2015), 5796–5806.
25. [25] Heinicke, U., Kupka, J., Fichter, I., Fulda, S., Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma. Oncogene, 2015 [E-pub ahead of print].
26. [26] Tchoghandjian, A., Jennewein, C., Eckhardt, I., Rajalingam, K., Fulda, S., Identification of non-canonical NF-kappaB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. Cell Death Dis, 4, 2013, e564.
27. [27] Roesler, S., Eckhardt, I., Wolf, S., Fulda, S., Cooperative TRAIL production mediates IFNα/Smac mimetic-induced cell death in TNFα-resistant solid cancer cells. Oncotarget 7 (2016), 3709–3725.
28. [28] Petersen, S.L., Wang, L., Yalcin-Chin, A., Li, L., Peyton, M., Minna, J., et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12 (2007), 445–456.
29. [29] Vince, J.E., Wong, W.W., Khan, N., Feltham, R., Chau, D., Ahmed, A.U., et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131 (2007), 682–693.
30. [30] Hitomi, J., Christofferson, D.E., Ng, A., Yao, J., Degterev, A., Xavier, R.J., et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 135 (2008), 1311–1323.
31. [31] Chopra, M., Lang, I., Salzmann, S., Pachel, C., Kraus, S., Bauerlein, C.A., et al. Tumor necrosis factor induces tumor promoting and anti-tumoral effects on pancreatic cancer via TNFR1. PLoS ONE, 8, 2013, e75737.
32. [32] Egberts, J.H., Cloosters, V., Noack, A., Schniewind, B., Thon, L., Klose, S., et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 68 (2008), 1443–1450.
33. [33] Balkwill, F., Tumour necrosis factor and cancer. Nat. Rev. Cancer 9 (2009), 361–371.
34. [34] Murugesan, S.R., King, C.R., Osborn, R., Fairweather, W.R., O'Reilly, E.M., Thornton, M.O., et al. Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer. Cancer Gene Ther 16 (2009), 841–847.
35. [35] Steinhart, L., Belz, K., Fulda, S., Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis, 4, 2013, e802.
36. [36] Gerges, S., Rohde, K., Fulda, S., Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells. Cancer Lett 375 (2016), 127–132.
37. [37] Chromik, J., Safferthal, C., Serve, H., Fulda, S., Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. Cancer Lett 344 (2014), 101–109.
38. [38] Steinwascher, S., Nugues, A.L., Schoeneberger, H., Fulda, S., Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells. Cancer Lett 366 (2015), 32–43.
39. [39] Laukens, B., Jennewein, C., Schenk, B., Vanlangenakker, N., Schier, A., Cristofanon, S., et al. Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor alpha-induced necroptosis. Neoplasia 13 (2011), 971–979.
40. [40] Talar-Wojnarowska, R., Gasiorowska, A., Smolarz, B., Romanowicz-Makowska, H., Kulig, A., Malecka-Panas, E., Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma 56 (2009), 56–62.
41. [41] Zhang, D.W., Shao, J., Lin, J., Zhang, N., Lu, B.J., Lin, S.C., et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325 (2009), 332–336.
42. [42] Cho, Y.S., Challa, S., Moquin, D., Genga, R., Ray, T.D., Guildford, M., et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137 (2009), 1112–1123.
43. [43] He, S., Wang, L., Miao, L., Wang, T., Du, F., Zhao, L., et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137 (2009), 1100–1111.
44. [44] Colbert, L.E., Fisher, S.B., Hardy, C.W., Hall, W.A., Saka, B., Shelton, J.W., et al. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. Cancer 119 (2013), 3148–3155.
45. [45] Voigt, S., Philipp, S., Davarnia, P., Winoto-Morbach, S., Roder, C., Arenz, C., et al. TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells. BMC Cancer, 14, 2014, 74.
46. [46] Pietkiewicz, S., Eils, R., Krammer, P.H., Giese, N., Lavrik, I.N., Combinatorial treatment of CD95L and gemcitabine in pancreatic cancer cells induces apoptotic and RIP1-mediated necroptotic cell death network. Exp. Cell Res 339 (2015), 1–9.